Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients

被引：0
|
作者：
Mustafa, Shokhan Mohammad [1 ]
Yassin, Ahmed Khudair [2 ]
Mohammed, Nawsherwan S. [2 ]
Shamoon, Rawand P. [2 ]
Karma, Marwa N. [1 ]
Mohammad, Shlan S. [1 ]
Abdulrahman, Lara Lateef [1 ]
Ahmed, Zhalla O. [1 ]
Rashid, Bryar Sabah [1 ]
Mahmood, Tavan I. [1 ]
Yousif, Rozhhat A. [1 ]
Hasan, Kawa M. [2 ]
Mohamed, Zaki A. [2 ]
Getta, Hisham A. [1 ]
Jalal, Sana D. [2 ]
Abdullah, Dana A. [2 ]
Abdulla, Basil K. [1 ]
Numan, Ghanim S. [1 ]
Karadagh, Ranan [2 ]
机构：
[1] Minist Hlth, Erbil, Iraq
[2] Minist Higher Educ, Erbil, Iraq
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; rituximab; chronic lymphocytic leukemia; complete response; cyclophosphamide; fludarabine; survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-035
引用
收藏
页码：S260 / S261
页数：2
相关论文
共 50 条
  • [1] Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Mohammed, Nawsherwan S.
    Shamoon, Rawand P.
    Karam, Marwa N.
    Mohammad, Shlan S.
    Abdulrahman, Lara Lateef
    Ahmed, Zhalla O.
    Rashid, Bryar Sabah
    Mahmood, Tavan, I
    Yousif, Rozhhat A.
    Hasan, Kawa M.
    Mohamed, Zeki A.
    Getta, Hisham A.
    Jalal, Sana D.
    Abdullah, Dana A.
    Abdulla, Basil K.
    Numan, Ghanim S.
    Karadagh, Ranan
    IRAQI JOURNAL OF HEMATOLOGY, 2021, 10 (02) : 139 - 145
  • [2] Long-Term Survival After Fludarabine, Cyclophosphamide, and Rituximab Treatment in Previously Untreated Chronic Lymphocytic Leukemia Patients
    Mustafa, Shokhan Mohammad
    Yassin, Ahmed Khudair
    Hassan, Kawa M.
    Sadiq, Nawsherwan
    Nadihm, Marwa N.
    Abdulrahman, Lara Lateef
    Salahaden, Shlan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S263 - S264
  • [3] Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia
    Hornberger, John
    Reyes, Carolina
    Shewade, Ashwini
    Lerner, Susan
    Friedmann, Mark
    Han, Leona
    Gutierrez, Hialy
    Satram-Hoang, Sacha
    Keating, Michael J.
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 225 - 234
  • [4] Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia
    Garrote H.
    Fuente A.
    Oña R.
    Rodríguez I.
    Echevarría J.E.
    Sepúlveda J.M.
    García J.F.
    Experimental Hematology & Oncology, 4 (1)
  • [5] A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
    Izutsu, Koji
    Kinoshita, Tomohiro
    Takizawa, Jun
    Fukuhara, Suguru
    Yamamoto, Go
    Ohashi, Yasuo
    Suzumiya, Junji
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 408 - 415
  • [6] COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE
    Roussel, M.
    Troussard, X.
    Delmer, A.
    Poinso, M.
    Miadi-Fargier, H.
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [7] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [8] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [9] Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL).
    Tarhini, A. A.
    Land, S.
    Lim, F.
    Kiefer, G. J.
    Pietragallo, L.
    Pinkerton, R. A.
    Sulecki, M.
    Meisner, D.
    Schaefer, P. M.
    Foon, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [10] Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Foon, Kenneth A.
    Boyiadzis, Michael
    Land, Stephanie R.
    Marks, Stanley
    Raptis, Anastasios
    Pietragallo, Louis
    Meisner, Dennis
    Laman, Andrew
    Sulecki, Mathew
    Butchko, Allyson
    Schaefer, Patricia
    Lenzer, Diana
    Tarhini, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 498 - 503
12345